Daniel Louis Hertz (Dan L Hertz, Daniel L Hertz)

ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 39

Top Venues

Pharmacogenomics

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical pharmacology and therapeutics

Breast cancer research and treatment

University of Michigan

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Michigan Apr 1o 2013

United States

Assistant Professor :: Clinical Pharmacy

Publications

Delaney V Rutherford, Sarah Medley, Nicholas C Henderson, Christina L Gersch, Ted A Vandenberg, Kathy S Albain, Shaker R Dakhil, Nagendra R Tirumali, Julie R Gralow, Gabriel N Hortobagyi, Lajos Pusztai, Rita S Mehta, Daniel F Hayes, Kelley M Kidwell, Norah L Henry, William E Barlow, James M Rae, Daniel Louis Hertz
Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. Pharmacogenomics (2023)
Ciao-Sin Chen, Gary Zirpoli, G Thomas Budd, William E Barlow, Lajos Pusztai, Gabriel N Hortobagyi, Kathy S Albain, Andrew K Godwin, Alastair Thompson, N Lynn Henry, Christine B Ambrosone, Kathleen A Stringer, Daniel Louis Hertz
Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221. Research square (2023)
Sharyn D Baker, Susan E Bates, Gabriel A Brooks, William L Dahut, Robert B Diasio, Wafik S El-Deiry, William E Evans, William Douglas Figg, Daniel Louis Hertz, J Kevin Hicks, Suneel D Kamath, Pashtoon Murtaza Kasi, Todd C Knepper, Howard L McLeod, Peter H O'Donnell, Mary V Relling, Michelle A Rudek, Tristan M Sissung, D Max Smith, Alex Sparreboom, Sandra M Swain, Christine M Walko
DPYD Testing: Time to Put Patient Safety First. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Daniel Louis Hertz, Maryam B Lustberg, Stephen T Sonis
Evolution of predictive risk factor analysis for chemotherapy-related toxicity. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 31 (10) (2023)
Daniel Louis Hertz, D Max Smith, Stuart A Scott, Jai Narendra Patel, J Kevin Hicks
Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy. Clinical pharmacology and therapeutics (2023)
Nathan D Seligson, Jill M Kolesar, Benish Alam, Laura Baker, Jatinder Kaur Lamba, Brooke L Fridley, Ameen A Salahudeen, Daniel Louis Hertz, J Kevin Hicks
Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer. Pharmacogenomics (2023)
Amy L Pasternak, Robinson Seda, Joseph Lipa, Rachel L McDevitt, Oxana V Crysler, Paul L Swiecicki, Bryan J Schneider, Brett Vanderwerff, Norah L Henry, John C Krauss, Vaibhav Sahai, Daniel Louis Hertz
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository. Clinical pharmacology and therapeutics (2023)
Daniel Louis Hertz
Reply to H.S. Hochster. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Daniel Louis Hertz, Li Chen, Norah L Henry, Jennifer J Griggs, Daniel F Hayes, Brian A Derstine, Grace L Su, Stewart C Wang, Manjunath Amit P Pai
Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing. British journal of clinical pharmacology 88 (7) (2022)
Kyoin Koo, Amy L Pasternak, Norah L Henry, Vaibhav Sahai, Daniel Louis Hertz
Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy. JCO oncology practice 18 (6) (2022)
Keneuoe Cecilia Nthontho, Andrew Khulekani Ndlovu, Kirthana Sharma, Ishmael Kasvosve, Daniel Louis Hertz, Giacomo Maria Paganotti
Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective. Pharmacogenomics and personalized medicine 15 (2022)
Daniel Louis Hertz, Lisa Meier McShane, Daniel F Hayes
Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (16) (2022)
Ciao-Sin Chen, Ellen M Lavoie Smith, Kathleen A Stringer, N Lynn Henry, Daniel Louis Hertz
Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel. Breast cancer research and treatment 194 (3) (2022)
Daniel Louis Hertz
Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (33) (2022)
Mary Hwang, Sarah Medley, Faisal Shakeel, Brett Vanderwerff, Matthew Zawistowski, Kelley M Kidwell, Daniel Louis Hertz
Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 30 (9) (2022)
Daniel Louis Hertz, Meghan J Arwood, Gabriele Stocco, Sonal Singh, Jason H Karnes, Laura B Ramsey
Planning and Conducting a Pharmacogenetics Association Study. Clinical pharmacology and therapeutics 110 (3) (2021)
Daniel Louis Hertz
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships. Expert opinion on drug metabolism & toxicology 17 (2) (2021)
Lauren Schumacher, Fang Fang, Kelley M Kidwell, Faisal Shakeel, Daniel Louis Hertz, Jeong Mi Park, Amy L Pasternak
SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolate. Pharmacogenomics 22 (17) (2021)
Yuanhuang Chen, Lauren A Marcath, Finn Magnus Eliassen, Tone Hoel Lende, Havard Soiland, Gunnar Mellgren, Thomas Helland, Daniel Louis Hertz
Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. Journal of personalized medicine 11 (6) (2021)
Li Chen, Ciao-Sin Chen, Yihan Sun, N Lynn Henry, Kathleen A Stringer, Daniel Louis Hertz
Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability. Cancer chemotherapy and pharmacology 88 (3) (2021)
Lauren A Marcath, Colin M Finley, Siu Fun Wong, Daniel Louis Hertz
Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy. BMC cancer 21 (1) (2021)
Thomas Helland, Sarah Alsomairy, Chenchia Lin, Håvard Søiland, Gunnar Mellgren, Daniel Louis Hertz
Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. Journal of personalized medicine 11 (3) (2021)
Ciao-Sin Chen, Judith Kim, Noemi Garg, Harsha Guntupalli, Reshma Jagsi, Jennifer J Griggs, Michael S Sabel, Michael P Dorsch, Brian Christopher Callaghan, Daniel Louis Hertz
Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study. JMIR mHealth and uHealth 9 (7) (2021)
Faisal Shakeel, Fang Fang, Jung Won Kwon, Kyoin Koo, Amy L Pasternak, Norah L Henry, Vaibhav Sahai, Kelley M Kidwell, Daniel Louis Hertz
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy. Pharmacogenomics 22 (3) (2021)
Jacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, Andrea M Pesch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd C Skaar, Daniel F Hayes, N Lynn Henry, James M Rae, Daniel Louis Hertz
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. Pharmacogenomics 20 (8) (2020)
Daniel Louis Hertz, Kelley M Kidwell, Julie A Douglas, Giuseppe Viale, Brian Leyland-Jones, Meredith Regan, James M Rae
DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses. Pharmacogenomics 21 (13) (2020)
Faisal Shakeel, Fang Fang, Kelley M Kidwell, Lauren A Marcath, Daniel Louis Hertz
Comparison of eight screening tools to detect interactions between herbal supplements and oncology agents. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (8) (2020)
Lauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, Christina L Gersch, James M Rae, Monika L Burness, Jennifer J Griggs, Catherine Van Poznak, Daniel F Hayes, Ellen M Lavoie Smith, N Lynn Henry, Andreas S Beutler, Daniel Louis Hertz
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. British journal of clinical pharmacology 86 (5) (2020)
Catherine Van Poznak, Evan L Reynolds, Cherry L Estilo, Mimi Hu, Bryan Paul Schneider, Daniel Louis Hertz, Christina Gersch, Jacklyn Thibert, Dafydd Thomas, Mousumi Banerjee, James M Rae, Daniel F Hayes
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral diseases (2020)
Yongzhen Chen, Fang Fang, Kelley M Kidwell, Kiran Vangipuram, Lauren A Marcath, Christina L Gersch, James M Rae, Daniel F Hayes, Ellen M Lavoie Smith, N Lynn Henry, Andreas S Beutler, Daniel Louis Hertz
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Pharmacogenomics 21 (12) (2020)
Theodore S Jennaro, Fang Fang, Kelley M Kidwell, Ellen M Lavoie Smith, Kiran Vangipuram, Monika L Burness, Jennifer J Griggs, Catherine Van Poznak, Daniel F Hayes, N Lynn Henry, Daniel Louis Hertz
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast cancer research and treatment 180 (3) (2020)
Daniel Louis Hertz
Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy. The pharmacogenomics journal 19 (5) (2019)
Lauren A Marcath, Amy L Pasternak, Daniel Louis Hertz
Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. The pharmacogenomics journal 19 (6) (2019)
Lauren A Marcath, Taylor D Coe, Emily K Hoylman, Bruce G Redman, Daniel Louis Hertz
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials. BMC cancer 18 (1) (2018)
Daniel Louis Hertz, Kelley M Kidwell, Kiran Vangipuram, Feng Li, Manjunath P Pai, Monika Burness, Jennifer J Griggs, Anne F Schott, Catherine Van Poznak, Daniel F Hayes, Ellen M Lavoie Smith, N Lynn Henry
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (15) (2018)
Yihan Sun, Jae Hyun Kim, Kiran Vangipuram, Daniel F Hayes, Ellen M L Smith, Larisa Yeomans, N Lynn Henry, Kathleen A Stringer, Daniel Louis Hertz
Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast cancer research and treatment 171 (3) (2018)
Amy L Pasternak, Kristen M Ward, Jasmine A Luzum, Vicki L Ellingrod, Daniel Louis Hertz
Germline genetic variants with implications for disease risk and therapeutic outcomes. Physiological genomics 49 (10) (2017)
Jacqueline M Dempsey, Jingyue Xi, N Lynn Henry, James M Rae, Daniel Louis Hertz
Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer. Physiological genomics 50 (2) (2017)
Daniel Louis Hertz, N Lynn Henry, Kelley M Kidwell, Dafydd Thomas, Audrey Goddard, Faouzi Azzouz, Kelly Speth, Lang Li, Mousumi Banerjee, Jacklyn N Thibert, Celina G Kleer, Vered Stearns, Daniel F Hayes, Todd C Skaar, James M Rae
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. Physiological genomics 48 (9) (2016)

Daniel Louis Hertz.css-eqlu8i{font-size:small;padding-left:4px;} (Dan L Hertz, Daniel L Hertz)

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Louis Hertz (Dan L Hertz, Daniel L Hertz)